Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis

Line Dam Heftdal, Anne Gitte Loft, Oliver Hendricks, Alice Ashouri Christiansen, Berit Schiøttz-Christensen, Bodil Arnbak, Anne Grethe Jurik, René Østgård, Bent Winding Deleuran, Holger Jon Møller, Stinne Ravn Greisen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The chronic joint inflammation in axial spondyloarthritis (axSpA) is characterized by infiltration of activated macrophages. The haptoglobin–hemoglobin receptor CD163 and the mannose receptor CD206 are strongly expressed on M2c and M2a macrophages, respectively. We measured the soluble forms of the receptors (sCD163 and sCD206) in plasma (PL) in two axSpA cohorts. All patients fulfil the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA and/or the 1984 modified New York criteria for ankylosing spondylitis. The first cohort included anti-TNF-α treated patients with active axSpA (n = 30); the second cohort included patients in early disease stages (n = 38). Plasma sCD163 and sCD206 were both within the reference interval of healthy controls (HC), but sCD163 decreased slightly during anti-TNF-α treatment [baseline: 1.49 mg/L (IQR: 1.22–1.77 mg/L, 12 weeks: 1.29 (IQR: 1.09–1.57) mg/L, 20 weeks: 1.25 (IQR: 0.99–1.75) mg/L, 52 weeks: 1.39 (IQR: 1.15–1.78) mg/L], while sCD206 increased [baseline: 0.17 (IQR: 0.13–0.21) mg/L, 12 weeks: 0.19 (0.16–0.23) mg/L, 20 weeks: 0.20 (0.14–0.24) mg/L, 52: 0.19 (IQR: 0.14–0.23) mg/L], pointing toward a shift in polarization of involved macrophages. Plasma levels of sCD206 proved significantly higher in patients with early disease stages and definite radiological sacroiliitis (n = 10). This was not the case for sCD163. A significant increase in response to anti-TNF-α treatment, could suggest sCD206 as a marker of response to anti-TNF-α treatment, however, the potential for the two macrophage markers as diagnostic and prognostic indicators of disease in axSpA is weak.

Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Volume78
Issue number6
Pages (from-to)483-489
ISSN0036-5513
DOIs
Publication statusPublished - 4. Sep 2018

Fingerprint

Macrophages
Joints

Keywords

  • biomarkers
  • CD163
  • macrophages
  • mannose receptor
  • receptors
  • scavenger
  • spondylarthritis
  • Humans
  • Middle Aged
  • Antigens, CD/blood
  • Male
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors
  • Mannose-Binding Lectins/blood
  • Sacroiliitis/diagnosis
  • Lectins, C-Type/blood
  • Adult
  • Biomarkers/blood
  • Female
  • Adalimumab/therapeutic use
  • Gene Expression
  • Solubility
  • Receptors, Cell Surface/blood
  • Macrophage Activation
  • Radiography
  • Anti-Inflammatory Agents/therapeutic use
  • Macrophages/drug effects
  • Spondylarthritis/diagnosis
  • Antigens, Differentiation, Myelomonocytic/blood
  • Early Diagnosis
  • Cell Movement
  • Cohort Studies

Cite this

@article{19e3f01d43114209be1b17467cb82b4c,
title = "Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis",
abstract = "The chronic joint inflammation in axial spondyloarthritis (axSpA) is characterized by infiltration of activated macrophages. The haptoglobin–hemoglobin receptor CD163 and the mannose receptor CD206 are strongly expressed on M2c and M2a macrophages, respectively. We measured the soluble forms of the receptors (sCD163 and sCD206) in plasma (PL) in two axSpA cohorts. All patients fulfil the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA and/or the 1984 modified New York criteria for ankylosing spondylitis. The first cohort included anti-TNF-α treated patients with active axSpA (n = 30); the second cohort included patients in early disease stages (n = 38). Plasma sCD163 and sCD206 were both within the reference interval of healthy controls (HC), but sCD163 decreased slightly during anti-TNF-α treatment [baseline: 1.49 mg/L (IQR: 1.22–1.77 mg/L, 12 weeks: 1.29 (IQR: 1.09–1.57) mg/L, 20 weeks: 1.25 (IQR: 0.99–1.75) mg/L, 52 weeks: 1.39 (IQR: 1.15–1.78) mg/L], while sCD206 increased [baseline: 0.17 (IQR: 0.13–0.21) mg/L, 12 weeks: 0.19 (0.16–0.23) mg/L, 20 weeks: 0.20 (0.14–0.24) mg/L, 52: 0.19 (IQR: 0.14–0.23) mg/L], pointing toward a shift in polarization of involved macrophages. Plasma levels of sCD206 proved significantly higher in patients with early disease stages and definite radiological sacroiliitis (n = 10). This was not the case for sCD163. A significant increase in response to anti-TNF-α treatment, could suggest sCD206 as a marker of response to anti-TNF-α treatment, however, the potential for the two macrophage markers as diagnostic and prognostic indicators of disease in axSpA is weak.",
keywords = "biomarkers, CD163, macrophages, mannose receptor, receptors, scavenger, spondylarthritis, Humans, Middle Aged, Antigens, CD/blood, Male, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Mannose-Binding Lectins/blood, Sacroiliitis/diagnosis, Lectins, C-Type/blood, Adult, Biomarkers/blood, Female, Adalimumab/therapeutic use, Gene Expression, Solubility, Receptors, Cell Surface/blood, Macrophage Activation, Radiography, Anti-Inflammatory Agents/therapeutic use, Macrophages/drug effects, Spondylarthritis/diagnosis, Antigens, Differentiation, Myelomonocytic/blood, Early Diagnosis, Cell Movement, Cohort Studies",
author = "Heftdal, {Line Dam} and Loft, {Anne Gitte} and Oliver Hendricks and {Ashouri Christiansen}, Alice and Berit Schi{\o}ttz-Christensen and Bodil Arnbak and Jurik, {Anne Grethe} and Ren{\'e} {\O}stg{\aa}rd and {Winding Deleuran}, Bent and M{\o}ller, {Holger Jon} and Greisen, {Stinne Ravn}",
year = "2018",
month = "9",
day = "4",
doi = "10.1080/00365513.2018.1500704",
language = "English",
volume = "78",
pages = "483--489",
journal = "Scandinavian Journal of Clinical & Laboratory Investigation",
issn = "0036-5513",
publisher = "Taylor & Francis",
number = "6",

}

Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis. / Heftdal, Line Dam; Loft, Anne Gitte; Hendricks, Oliver; Ashouri Christiansen, Alice; Schiøttz-Christensen, Berit; Arnbak, Bodil; Jurik, Anne Grethe; Østgård, René; Winding Deleuran, Bent; Møller, Holger Jon; Greisen, Stinne Ravn.

In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 78, No. 6, 04.09.2018, p. 483-489.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis

AU - Heftdal, Line Dam

AU - Loft, Anne Gitte

AU - Hendricks, Oliver

AU - Ashouri Christiansen, Alice

AU - Schiøttz-Christensen, Berit

AU - Arnbak, Bodil

AU - Jurik, Anne Grethe

AU - Østgård, René

AU - Winding Deleuran, Bent

AU - Møller, Holger Jon

AU - Greisen, Stinne Ravn

PY - 2018/9/4

Y1 - 2018/9/4

N2 - The chronic joint inflammation in axial spondyloarthritis (axSpA) is characterized by infiltration of activated macrophages. The haptoglobin–hemoglobin receptor CD163 and the mannose receptor CD206 are strongly expressed on M2c and M2a macrophages, respectively. We measured the soluble forms of the receptors (sCD163 and sCD206) in plasma (PL) in two axSpA cohorts. All patients fulfil the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA and/or the 1984 modified New York criteria for ankylosing spondylitis. The first cohort included anti-TNF-α treated patients with active axSpA (n = 30); the second cohort included patients in early disease stages (n = 38). Plasma sCD163 and sCD206 were both within the reference interval of healthy controls (HC), but sCD163 decreased slightly during anti-TNF-α treatment [baseline: 1.49 mg/L (IQR: 1.22–1.77 mg/L, 12 weeks: 1.29 (IQR: 1.09–1.57) mg/L, 20 weeks: 1.25 (IQR: 0.99–1.75) mg/L, 52 weeks: 1.39 (IQR: 1.15–1.78) mg/L], while sCD206 increased [baseline: 0.17 (IQR: 0.13–0.21) mg/L, 12 weeks: 0.19 (0.16–0.23) mg/L, 20 weeks: 0.20 (0.14–0.24) mg/L, 52: 0.19 (IQR: 0.14–0.23) mg/L], pointing toward a shift in polarization of involved macrophages. Plasma levels of sCD206 proved significantly higher in patients with early disease stages and definite radiological sacroiliitis (n = 10). This was not the case for sCD163. A significant increase in response to anti-TNF-α treatment, could suggest sCD206 as a marker of response to anti-TNF-α treatment, however, the potential for the two macrophage markers as diagnostic and prognostic indicators of disease in axSpA is weak.

AB - The chronic joint inflammation in axial spondyloarthritis (axSpA) is characterized by infiltration of activated macrophages. The haptoglobin–hemoglobin receptor CD163 and the mannose receptor CD206 are strongly expressed on M2c and M2a macrophages, respectively. We measured the soluble forms of the receptors (sCD163 and sCD206) in plasma (PL) in two axSpA cohorts. All patients fulfil the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA and/or the 1984 modified New York criteria for ankylosing spondylitis. The first cohort included anti-TNF-α treated patients with active axSpA (n = 30); the second cohort included patients in early disease stages (n = 38). Plasma sCD163 and sCD206 were both within the reference interval of healthy controls (HC), but sCD163 decreased slightly during anti-TNF-α treatment [baseline: 1.49 mg/L (IQR: 1.22–1.77 mg/L, 12 weeks: 1.29 (IQR: 1.09–1.57) mg/L, 20 weeks: 1.25 (IQR: 0.99–1.75) mg/L, 52 weeks: 1.39 (IQR: 1.15–1.78) mg/L], while sCD206 increased [baseline: 0.17 (IQR: 0.13–0.21) mg/L, 12 weeks: 0.19 (0.16–0.23) mg/L, 20 weeks: 0.20 (0.14–0.24) mg/L, 52: 0.19 (IQR: 0.14–0.23) mg/L], pointing toward a shift in polarization of involved macrophages. Plasma levels of sCD206 proved significantly higher in patients with early disease stages and definite radiological sacroiliitis (n = 10). This was not the case for sCD163. A significant increase in response to anti-TNF-α treatment, could suggest sCD206 as a marker of response to anti-TNF-α treatment, however, the potential for the two macrophage markers as diagnostic and prognostic indicators of disease in axSpA is weak.

KW - biomarkers

KW - CD163

KW - macrophages

KW - mannose receptor

KW - receptors

KW - scavenger

KW - spondylarthritis

KW - Humans

KW - Middle Aged

KW - Antigens, CD/blood

KW - Male

KW - Tumor Necrosis Factor-alpha/antagonists & inhibitors

KW - Mannose-Binding Lectins/blood

KW - Sacroiliitis/diagnosis

KW - Lectins, C-Type/blood

KW - Adult

KW - Biomarkers/blood

KW - Female

KW - Adalimumab/therapeutic use

KW - Gene Expression

KW - Solubility

KW - Receptors, Cell Surface/blood

KW - Macrophage Activation

KW - Radiography

KW - Anti-Inflammatory Agents/therapeutic use

KW - Macrophages/drug effects

KW - Spondylarthritis/diagnosis

KW - Antigens, Differentiation, Myelomonocytic/blood

KW - Early Diagnosis

KW - Cell Movement

KW - Cohort Studies

U2 - 10.1080/00365513.2018.1500704

DO - 10.1080/00365513.2018.1500704

M3 - Journal article

C2 - 30176763

AN - SCOPUS:85053250201

VL - 78

SP - 483

EP - 489

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

SN - 0036-5513

IS - 6

ER -